Oncology and therapy

Keyphrases

Publications

volume 12, number 2, 2024

Scarlette Pacis, Anna Bolzani, Alexander Heuck, Klaus Gossens, Mathias Kruse, Björn Fritz, Ulf Maywald, Thomas Wilke, Christian Kunz
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis. Oncology and therapy 12 (2) (2024)
Ruofei Yuan, Bo Wang, Ying Wang, Pi-Nan Liu
Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions. Oncology and therapy 12 (2) (2024)

volume 12, number 3, 2024

Mirosława Püsküllüoğlu, Małgorzata Pieniążek, Agnieszka Rudzińska, Agnieszka Pietruszka, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marek Ziobro
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis. Oncology and therapy 12 (3) (2024)
Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy 12 (3) (2024)
Luca Scafuri, Carlo Buonerba, Vincenzo Di Lauro, Vincenzo Tortora, Marco Cascella, Luigi Liguori, Antonella Sciarra, Francesco Sabbatino, Anna Diana, Antonio Marra, Paolo Tarantino, Dario Trapani, Mario Giuliano, Grazia Arpino, Giuseppe Curigliano, Giuseppe Di Lorenzo
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy. Oncology and therapy 12 (3) (2024)
Márcia Torresan Delamain, Ana Carolina Ferreira Cardoso, Fernando Vieira Pericole, Sérgio Shusterschitz da Silva Araújo, Laura Fogliatto, Marcia Higashi, Juliana Pereira, Roberto Luiz da Silva, Gustavo Werutsky, Patrícia de Paulo Giacon Radtke, Marco Aurélio Salvino, Vivienne Carduz Castilho
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma. Oncology and therapy 12 (3) (2024)
Ava Kwong, Roland Leung, Tsz Ching Chan, Anvi Khandelwal, Kshama Mishra, Min Huang
Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong. Oncology and therapy 12 (3) (2024)
Yang Zhou, Yu-Lun Chen, Xi-Yi Huang, Ying-Jun Chang
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know. Oncology and therapy 12 (3) (2024)
Ava Kwong, Roland Leung, Tsz Ching Chan, Anvi Khandelwal, Kshama Mishra, Min Huang
Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong. Oncology and therapy 12 (3) (2024)
Ryan D Gentzler, John Guittar, Akash Mitra, Wade T Iams, Terri Driessen, Regina Schwind, Michelle M Stein, Kristiyana Kaneva, Seung Won Hyun, Yan Liu, Adam J Dugan, Cecile Rose T Vibat, Chithra Sangli, Jonathan Freaney, Zachary Rivers, Josephine L Feliciano, Christine Lo, Kate Sasser, Rotem Ben-Shachar, Halla Nimeiri, Jyoti D Patel, Aadel A Chaudhuri
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy. Oncology and therapy 12 (3) (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy 12 (3) (2024)
Alison Jane Birtle, Luigi Formisano, Vincent Descamps, Peter Weisenseel, Antoni Vilaseca
Early Identification and Management of Patients with Rash on Apalutamide. Oncology and therapy 12 (3) (2024)
Ava Kwong, Roland Leung, Tsz Ching Chan, Anvi Khandelwal, Kshama Mishra, Min Huang
Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong. Oncology and therapy 12 (3) (2024)
Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy 12 (3) (2024)
Ryan D Gentzler, John Guittar, Akash Mitra, Wade T Iams, Terri Driessen, Regina Schwind, Michelle M Stein, Kristiyana Kaneva, Seung Won Hyun, Yan Liu, Adam J Dugan, Cecile Rose T Vibat, Chithra Sangli, Jonathan Freaney, Zachary Rivers, Josephine L Feliciano, Christine Lo, Kate Sasser, Rotem Ben-Shachar, Halla Nimeiri, Jyoti D Patel, Aadel A Chaudhuri
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy. Oncology and therapy 12 (3) (2024)
Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy 12 (3) (2024)
Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study. Oncology and therapy 12 (3) (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy 12 (3) (2024)
Alison Jane Birtle, Luigi Formisano, Vincent Descamps, Peter Weisenseel, Antoni Vilaseca
Early Identification and Management of Patients with Rash on Apalutamide. Oncology and therapy 12 (3) (2024)
Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy 12 (3) (2024)
Mirosława Püsküllüoğlu, Małgorzata Pieniążek, Agnieszka Rudzińska, Agnieszka Pietruszka, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marek Ziobro
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis. Oncology and therapy 12 (3) (2024)
Dana M Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A Hurteau, Jeanne M Schilder
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study. Oncology and therapy 12 (3) (2024)
Mirosława Püsküllüoğlu, Małgorzata Pieniążek, Agnieszka Rudzińska, Agnieszka Pietruszka, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marek Ziobro
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis. Oncology and therapy 12 (3) (2024)
Elizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, Ameur Manceur, Selvam Sendhill, Eric Wu
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC. Oncology and therapy 12 (3) (2024)
Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy 12 (3) (2024)
Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study. Oncology and therapy 12 (3) (2024)
Matthew Franklin, Francis Shupo, Grace Wayi-Wayi, Natasa Zibelnik, Emily Jones, Nicola Mason, John E Brazier, Sudipto Mukherjee
Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease. Oncology and therapy 12 (3) (2024)
Elizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, Ameur Manceur, Selvam Sendhill, Eric Wu
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC. Oncology and therapy 12 (3) (2024)
Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy 12 (3) (2024)
Alison Jane Birtle, Luigi Formisano, Vincent Descamps, Peter Weisenseel, Antoni Vilaseca
Early Identification and Management of Patients with Rash on Apalutamide. Oncology and therapy 12 (3) (2024)
Matthew Franklin, Francis Shupo, Grace Wayi-Wayi, Natasa Zibelnik, Emily Jones, Nicola Mason, John E Brazier, Sudipto Mukherjee
Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease. Oncology and therapy 12 (3) (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy 12 (3) (2024)
Luca Scafuri, Carlo Buonerba, Vincenzo Di Lauro, Vincenzo Tortora, Marco Cascella, Luigi Liguori, Antonella Sciarra, Francesco Sabbatino, Anna Diana, Antonio Marra, Paolo Tarantino, Dario Trapani, Mario Giuliano, Grazia Arpino, Giuseppe Curigliano, Giuseppe Di Lorenzo
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy. Oncology and therapy 12 (3) (2024)
Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy 12 (3) (2024)
Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy 12 (3) (2024)
Dana M Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A Hurteau, Jeanne M Schilder
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study. Oncology and therapy 12 (3) (2024)
Dana M Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A Hurteau, Jeanne M Schilder
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study. Oncology and therapy 12 (3) (2024)
Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy 12 (3) (2024)
Elizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, Ameur Manceur, Selvam Sendhill, Eric Wu
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC. Oncology and therapy 12 (3) (2024)
Márcia Torresan Delamain, Ana Carolina Ferreira Cardoso, Fernando Vieira Pericole, Sérgio Shusterschitz da Silva Araújo, Laura Fogliatto, Marcia Higashi, Juliana Pereira, Roberto Luiz da Silva, Gustavo Werutsky, Patrícia de Paulo Giacon Radtke, Marco Aurélio Salvino, Vivienne Carduz Castilho
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma. Oncology and therapy 12 (3) (2024)
Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study. Oncology and therapy 12 (3) (2024)
Matthew Franklin, Francis Shupo, Grace Wayi-Wayi, Natasa Zibelnik, Emily Jones, Nicola Mason, John E Brazier, Sudipto Mukherjee
Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease. Oncology and therapy 12 (3) (2024)
Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy 12 (3) (2024)
Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy 12 (3) (2024)
Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy 12 (3) (2024)
Márcia Torresan Delamain, Ana Carolina Ferreira Cardoso, Fernando Vieira Pericole, Sérgio Shusterschitz da Silva Araújo, Laura Fogliatto, Marcia Higashi, Juliana Pereira, Roberto Luiz da Silva, Gustavo Werutsky, Patrícia de Paulo Giacon Radtke, Marco Aurélio Salvino, Vivienne Carduz Castilho
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma. Oncology and therapy 12 (3) (2024)
Yang Zhou, Yu-Lun Chen, Xi-Yi Huang, Ying-Jun Chang
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know. Oncology and therapy 12 (3) (2024)
Ryan D Gentzler, John Guittar, Akash Mitra, Wade T Iams, Terri Driessen, Regina Schwind, Michelle M Stein, Kristiyana Kaneva, Seung Won Hyun, Yan Liu, Adam J Dugan, Cecile Rose T Vibat, Chithra Sangli, Jonathan Freaney, Zachary Rivers, Josephine L Feliciano, Christine Lo, Kate Sasser, Rotem Ben-Shachar, Halla Nimeiri, Jyoti D Patel, Aadel A Chaudhuri
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy. Oncology and therapy 12 (3) (2024)
Luca Scafuri, Carlo Buonerba, Vincenzo Di Lauro, Vincenzo Tortora, Marco Cascella, Luigi Liguori, Antonella Sciarra, Francesco Sabbatino, Anna Diana, Antonio Marra, Paolo Tarantino, Dario Trapani, Mario Giuliano, Grazia Arpino, Giuseppe Curigliano, Giuseppe Di Lorenzo
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy. Oncology and therapy 12 (3) (2024)
Yang Zhou, Yu-Lun Chen, Xi-Yi Huang, Ying-Jun Chang
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know. Oncology and therapy 12 (3) (2024)